Portfolio PR – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

Sound Bioventures - Team 2025

Sound Bioventures 2025 Achievements & Highlights

2025.12.172025.12.17 / Our mission is driving innovation in life sciences by backing transformative companies addressing high unmet medical needs. We have added two new Principals to our investment team During the ye ...

AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b

2025.12.102025.12.10 / December 10, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announces strong topline results from the Pha ...

BOOST Pharma Pressrelease

BOOST Pharma Adds Sound Bioventures to Investor Syndicate to Advance Stem Cell Therapy for Osteogenesis Imperfecta

2025.11.032025.11.03 / Copenhagen, Denmark – November 3, 2025 – BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced ...

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer

2025.10.302025.12.02 / Gosselies, Belgium and Nantes, France, October 30, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering f ...

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

2025.10.132025.12.02 / THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical t ...

Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

2025.10.072025.12.02 / Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovaria ...

VarmX receives Phase 1 waiver from Japanese regulator PMDA

2025.09.252025.09.25 / for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go straight to Phase 3 development ...

AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025

2025.09.172025.12.02 / Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of ...

ARTHEx biotech

ARTHEx Biotech Upsizes Series B Financing Round to $87M

2025.09.172025.12.02 / to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines - Extension financing led by new investor Bpifrance, with renewed participation from al ...

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

2025.09.162025.12.02 / Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone ...

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

2025.09.022025.12.02 / Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces to ...

Breye Therapeutics ApS is featured on the latest episode of OptimumTV!

2025.08.212025.09.22 / CEO Ulrik Mouritzen joined Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study of orally administered hashtag#danegaptide, for the treatment ...